# bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

> **NCT06061276** · NA · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 40 (estimated)

## Conditions studied

- Liver Diseases
- Hepatocellular Carcinoma
- Immunotherapy
- Camrelizumab
- Lenvatinib

## Interventions

- **PROCEDURE:** bTAE-HAIC
- **DRUG:** Lenvatinib
- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT06061276
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-20
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06061276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06061276, "bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06061276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*